These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6765421)

  • 21. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposome encapsulated tumor-associated antigens elicited humoral and cellular immune responses in mice bearing tumor.
    Alam A; Imliwati L; Rapthap C; Singh V
    Indian J Exp Biol; 2001 Mar; 39(3):201-8. PubMed ID: 11495277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro.
    Dürrbach A; Angevin E; Poncet P; Rouleau M; Chavanel G; Chapel A; Thierry D; Gorter A; Hirsch R; Charpentier B; Senik A; Hirsch F
    Cancer Gene Ther; 1999; 6(6):564-71. PubMed ID: 10608353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoelectron microscopic localization of a tumor-associated antigen (TAA) in the canine transmissible venereal sarcoma by anti-TAA-antiferritin hybrid antibodies.
    Hill DL; Yang TJ
    J Natl Cancer Inst; 1985 Oct; 75(4):725-32. PubMed ID: 3900513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does caffeine reverse the EAC cell-induced immune suppression?
    Mandal A; Poddar MK
    J Pharm Pharmacol; 2007 Jul; 59(7):1001-9. PubMed ID: 17637196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-step single-chain Fv recombinant antibody-based purification of gp96 for vaccine development.
    Arnold-Schild D; Kleist C; Welschof M; Opelz G; Rammensee HG; Schild H; Terness P
    Cancer Res; 2000 Aug; 60(15):4175-8. PubMed ID: 10945626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor rejection activity of antigens isolated from the membranes of a methylcholanthrene-induced sarcoma, C-1, bearing alien H-2 antigens.
    Law LW; DuBois GC; Rogers MJ; Appella E; Pierotti MA; Parmiani G
    Transplant Proc; 1980 Mar; 12(1):46-9. PubMed ID: 6154358
    [No Abstract]   [Full Text] [Related]  

  • 28. [Study of the antigenic affinity between bacillus megaterium H. and ehrlich cancer cells in an anaphylaxis reaction with desensitization].
    Zatula DG; Severnikov VA
    Mikrobiol Zh; 1976; 38(2):220-4. PubMed ID: 820951
    [No Abstract]   [Full Text] [Related]  

  • 29. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
    Bolli M; Kocher T; Adamina M; Guller U; Dalquen P; Haas P; Mirlacher M; Gambazzi F; Harder F; Heberer M; Sauter G; Spagnoli GC
    Ann Surg; 2002 Dec; 236(6):785-93; discussion 793. PubMed ID: 12454517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
    Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
    J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Purification of colorectal cancer-associated antigen by immuno-affinity chromatography].
    Yang Y; Li Y; Wang XH; Shang P; Wang L; Qian AR; Yao XY; Chen ZN
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):348-51. PubMed ID: 15193236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy of Ehrlich ascites carcinoma (EAC) with antiserum to modified EAC.
    Das AK; Roy DK
    Indian J Exp Biol; 1985 Nov; 23(11):641-3. PubMed ID: 3833682
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells.
    DuBois GC; Appella E; Law LW; DeLeo AB; Old LJ
    Cancer Res; 1980 Nov; 40(11):4204-8. PubMed ID: 7471061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor immunity to murine plasma cell tumors. V. Genetic control of the in vitro cytotoxic T-cell response to plasma cell tumor-associated antigens of NZB mice.
    Burton RC; Warner NL
    J Natl Cancer Inst; 1980 Aug; 65(2):431-40. PubMed ID: 6967529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human T cell leukemia antigens on the cell membranes: purification molecular characterization, and preparation of specific antisera.
    Seon BK; Negoro S; Minowada J; Yoshizaki K
    J Immunol; 1981 Dec; 127(6):2580-8. PubMed ID: 6975329
    [No Abstract]   [Full Text] [Related]  

  • 36. Augmented immunogenicity of tumor cell homogenates produced by infection with influenza virus.
    Boone CW
    Natl Cancer Inst Monogr; 1972 Dec; 35():301-7. PubMed ID: 4349150
    [No Abstract]   [Full Text] [Related]  

  • 37. Modulation of TCR-mediated signaling pathway by thymic shared antigen-1 (TSA-1)/stem cell antigen-2 (Sca-2).
    Saitoh S; Kosugi A; Noda S; Yamamoto N; Ogata M; Minami Y; Miyake K; Hamaoka T
    J Immunol; 1995 Dec; 155(12):5574-81. PubMed ID: 7499840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation and modulation of Ehrlich ascites tumor growth with tumor-plasma IgA.
    Ghosh AK; Saha S
    Indian J Exp Biol; 2000 Apr; 38(4):313-22. PubMed ID: 11218806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
    J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.